A Phase 1 study of anti-human EGFR (Vectibix sequence) targeted EDVs carrying cytotoxic drug, siRNA or miRNA (VEDVsPayload) in Patients with Advanced Solid Tumours who have no curative treatment options.

Trial Profile

A Phase 1 study of anti-human EGFR (Vectibix sequence) targeted EDVs carrying cytotoxic drug, siRNA or miRNA (VEDVsPayload) in Patients with Advanced Solid Tumours who have no curative treatment options.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs MicroRNAs (Primary) ; Small interfering RNA (Primary) ; Doxorubicin; Gemcitabine; Maytansinoids; Mitoxantrone
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms Tailored EDV
  • Sponsors EnGeneIC
  • Most Recent Events

    • 03 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top